基石药业－Ｂ(02616.HK) 公布，与医药公司SteinCares达成商业化战略合作。根据许可及商业化协定，SteinCares将获得舒格利单抗在十个拉丁美洲国家，包括巴西、阿根廷、墨西哥、智利、哥伦比亚、哥斯达黎加、巴拿马、秘鲁、危地马拉及厄瓜多尔的商业化权利。
基石药业将获得首付款、注册与销售里程碑付款，以及通过在10个拉丁美洲国家向SteinCares销售舒格利单抗来获取收入。 这是基石药业就舒格利单抗达成的第三项重大全球商业化合作，预计近期将在西欧、东南亚及加拿大等地区达成更多商业化合作。基石药业已获得舒格利单抗在欧盟，欧洲经济区国家以及英国的上市许可，并正积极推进其他适应症的注册上市进程。 (ha/k)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.